Loading…
Climb Bio Inc is projected to rise to $19.09 by 2027, a +60% move from its current price of $11.90. CLYM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $11.56 | $11.92 | $12.29 | +0.13% |
| Aug 3 | $11.42 | $11.93 | $12.46 | +0.26% |
| Aug 4 | $11.33 | $11.95 | $12.60 | +0.38% |
| Aug 5 | $11.25 | $11.96 | $12.72 | +0.51% |
| Aug 6 | $11.18 | $11.98 | $12.83 | +0.64% |
| Aug 7 | $11.12 | $11.99 | $12.93 | +0.77% |
| Aug 8 | $11.07 | $12.01 | $13.02 | +0.90% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.07 | $12.01 | $13.02 | +0.90% |
| Week 2 | $10.80 | $12.12 | $13.59 | +1.81% |
| Week 3 | $10.62 | $12.22 | $14.07 | +2.72% |
| Week 4 | $10.49 | $12.33 | $14.51 | +3.65% |
| Week 5 | $10.38 | $12.45 | $14.92 | +4.58% |
| Week 6 | $10.30 | $12.56 | $15.32 | +5.52% |
| Week 7 | $10.22 | $12.67 | $15.70 | +6.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies to address unmet needs for patients living with immune-mediated diseases.
The lead product candidate is budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.
The company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc.
in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio, Inc. (CLYM) is a healthcare company whose current price is $12.58. It has a market capitalization of $720.37M and is ranked 2729 in market cap.
The forecast implies meaningful upside over the longer term, with multi-year price projections spanning 2026 to 2050 and bullish sentiment in most years.
A major floor 45.0% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 17.6% above — a clean break opens room to run.
A major ceiling 26.1% above — clearing it would confirm fresh momentum.
Key CLYM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLYM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.23 | Sell | $12.19 | Sell |
| MA 10 | $12.47 | Sell | $12.42 | Sell |
| MA 20 | $12.92 | Sell | $12.57 | Sell |
| MA 50 | $12.14 | Sell | $11.98 | Sell |
| MA 100 | $10.36 | Buy | $10.47 | Buy |
| MA 200 | $7.07 | Buy | $8.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.01 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -129.39 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -14.20 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | -0.42 | Sell |
| Ultimate (7,14,28) | 29.96 | Buy |
| Momentum (10) | -0.80 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 11.90 | Sell |
| ADX (14) | 13.52 | Neutral |
| ATR (14) | 0.34 | Info |
The 30-day technical picture for CLYM is bullish.
RSI14 is 50, and the shares are trading above the 50-day simple moving average of $11.84 and well above the 200-day simple moving average of $6.49.
Near-term support is at $10.44 and resistance at $14.00. The 30-day price range runs from a low of $9.93 to a high of $15.94, with annualized volatility at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.54 | $11.90 | $17.23 | 0% | Neutral | |
| $15.06 | $19.09 | $25.69 | +60% | Bullish | |
| $16.65 | $21.80 | $30.59 | +83% | Bullish | |
| $19.66 | $26.43 | $38.29 | +122% | Bullish | |
| $21.71 | $29.89 | $44.48 | +151% | Bullish | |
| $22.52 | $31.68 | $48.26 | +166% | Bullish | |
| $26.26 | $37.68 | $58.61 | +217% | Bullish | |
| $33.36 | $48.77 | $77.32 | +310% | Bullish | |
| $40.08 | $59.66 | $96.23 | +401% | Bullish | |
| $41.99 | $63.59 | $104.24 | +434% | Bullish | |
| $68.76 | $112.61 | $197.40 | +846% | Bullish | |
| $115.55 | $217.03 | $419.23 | +17.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.54 | $11.90 | $14.43 | +0.00% |
| September 2026 | $10.71 | $12.72 | $15.56 | +6.86% |
| October 2026 | $11.18 | $13.37 | $16.56 | +5.17% |
| November 2026 | $11.12 | $13.39 | $16.73 | +0.09% |
| December 2026 | $11.28 | $13.66 | $17.23 | +2.08% |
Click any year to see its month-by-month CLYM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLYM price prediction for 2026 points to an average of $11.90 (low $3.54, high $17.23) — a potential gain of 0% on today's $11.90. Price action looks broadly range-bound.
In 2027, CLYM is projected to trade between $15.06 and $25.69, averaging $19.09 — a potential gain of +60% from today's $11.90. That is up +60% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Climb Bio Inc's 2028 outlook centres on $21.80, within a $16.65 to $30.59 range. That is up +14% on the projected 2027 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2029, CLYM could reach as high as $38.29, with a base case around $26.43 and support toward $19.66 — roughly +122% from $11.90. Buyers look set to stay in control over this stretch.
Expect CLYM to range from $21.71 to $44.48 through 2030. The $29.89 average target implies a +151% move from current prices. That is up +13% on the projected 2029 average. Momentum favours further upside here.
The CLYM price prediction for 2031 points to an average of $31.68 (low $22.52, high $48.26) — a potential gain of +166% on today's $11.90. Buyers look set to stay in control over this stretch.
In 2032, CLYM is projected to trade between $26.26 and $58.61, averaging $37.68 — a potential gain of +217% from today's $11.90. That is up +19% on the projected 2031 average. Momentum favours further upside here.
Climb Bio Inc's 2033 outlook centres on $48.77, within a $33.36 to $77.32 range. That is up +29% on the projected 2032 average. That marks a +310% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CLYM could reach as high as $96.23, with a base case around $59.66 and support toward $40.08 — roughly +401% from $11.90. Momentum favours further upside here.
Expect CLYM to range from $41.99 to $104.24 through 2035. The $63.59 average target implies a +434% move from current prices. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CLYM price prediction for 2040 points to an average of $112.61 (low $68.76, high $197.40) — a potential gain of +846% on today's $11.90. Momentum favours further upside here.
In 2050, CLYM is projected to trade between $115.55 and $419.23, averaging $217.03 — a potential gain of +17.2x from today's $11.90. That is up +93% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLYM today (≈ 84.033613 CLYM) could be worth
$18,238.07
+$17,238.07 (+1724%) by 2050 · US Dollar
Based on the average projected CLYM price of $217.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLYMwould be worth at today's price.
$1,000 invested in CLYM on Jul 31, 2025 (≈ 714.285726 CLYM) would be worth
$8,500
+$7,500 (+750.0%) today · 8.50× · US Dollar
Based on a CLYM entry price of $1.4 vs. today's $11.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.84 | $926.79 | -7.3% |
| 1 month ago | $13.29 | $895.41 | -10.5% |
| 3 months ago | $8.91 | $1,335.58 | +33.6% |
| 6 months ago | $4.73 | $2,515.86 | +151.6% |
| 1 year ago | $1.4 | $8,500 | +750.0% |
| All time (5.0y) ago | $15.9 | $748.43 | -25.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLYM forecast.
Our base-case forecast reaches $24.00 around 2029.
Implied market cap at $24.00: $1.37B
The multi-year forecast shows a bullish trajectory with substantial upside through 2050. In 2026, the avg price is $12.58 with 0% ROI, reflecting a neutral outlook. The outlook grows more bullish from 2027 onward, with 2027 avg $20.50 and ROI 62.9%, 2028 avg $22.52 (ROI 79%), 2029 avg $28.00 (ROI 122.5%), 2030 avg $30.38 (ROI 141.5%), and 2031 avg $30.46 (ROI 142.2%).
By 2032, the avg is $38.40 (ROI 205.3%), 2033 avg $49.41 (ROI 292.8%), 2034 avg $58.94 (ROI 368.6%), and 2035 avg $63.82 (ROI 407.3%). The trajectory continues to 2040 with avg $108.99 (ROI 766.4%) and 2050 with avg $204.05 (ROI 1522%), all with bullish sentiment.
These figures illustrate a long-term rise in projected values, but they are estimates, not guarantees, and reflect the inherent uncertainty and risk in biotech development and equity markets.
Tap a question to reveal the answer.
2030 avg $30.38, min $21.29, max $46.99; ROI 141.5%; sentiment BULLISH.
Forecasts show a bullish trajectory across many years with rising avg prices and high ROI in later years (e.g., 2027 avg $20.50, ROI 62.9%; 2050 avg $204.05, ROI 1522%). These are estimates and not guarantees.
2035 max is $109.98, and 2040 max is $202.36, so a value near $110 is forecast for 2035.
Current price is $12.58 and market cap is $720.37M.
2040 min $61.61, avg $108.99, max $202.36; ROI 766.4%; sentiment BULLISH.
Climb Bio Inc Community Discussion
0Share your Climb Bio Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.